CLINICAL TRIALS PROFILE FOR CARDENE IN 5.0% DEXTROSE IN PLASTIC CONTAINER
✉ Email this page to a colleague
All Clinical Trials for Cardene In 5.0% Dextrose In Plastic Container
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00325793 ↗ | IV Double and Triple Concentrated Nicardipine for Stroke and ICH | Unknown status | PDL BioPharma, Inc. | Phase 4 | 2004-01-01 | Hypertension (high blood pressure) can often cause neurological worsening in patients with stroke, intracerebral hemorrhage and subarachnoid hemorrhage. Intravenous infusion of nicardipine (Cardene) for control of hypertension is FDA approved. The disadvantage of Nicardipine IV drip is the relative large volume of fluid needed (up to 150 cc/hr). The purpose of this study is to evaluate safety and efficacy of double or triple concentrated peripheral intravenous (IV) Nicardipine. |
| NCT00325793 ↗ | IV Double and Triple Concentrated Nicardipine for Stroke and ICH | Unknown status | OSF Healthcare System | Phase 4 | 2004-01-01 | Hypertension (high blood pressure) can often cause neurological worsening in patients with stroke, intracerebral hemorrhage and subarachnoid hemorrhage. Intravenous infusion of nicardipine (Cardene) for control of hypertension is FDA approved. The disadvantage of Nicardipine IV drip is the relative large volume of fluid needed (up to 150 cc/hr). The purpose of this study is to evaluate safety and efficacy of double or triple concentrated peripheral intravenous (IV) Nicardipine. |
| NCT00528827 ↗ | A Randomized, Double-blinded, Placebo-controlled, Dose-ranging Study of Cardene® I.V. in Pediatric Subjects With Hypertension | Withdrawn | Facet Biotech | Phase 2 | 2007-09-01 | To define the relationship between Cardene I.V. dose, serum concentrations, and blood pressure reduction in pediatric subjects with hypertension. |
| NCT00765648 ↗ | Evaluation of Intravenous Cardene(Nicardipine)and Labetalol Use in the Emergency Department | Completed | EKR Therapeutics, Inc | Phase 4 | 2008-10-01 | The purpose of this study is to compare the safety and efficacy of Cardene I.V. to labetalol administered intravenously for the management of hypertension in the emergency department setting. |
| NCT00765648 ↗ | Evaluation of Intravenous Cardene(Nicardipine)and Labetalol Use in the Emergency Department | Completed | The Cleveland Clinic | Phase 4 | 2008-10-01 | The purpose of this study is to compare the safety and efficacy of Cardene I.V. to labetalol administered intravenously for the management of hypertension in the emergency department setting. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for Cardene In 5.0% Dextrose In Plastic Container
Condition Name
| Condition Name for Cardene In 5.0% Dextrose In Plastic Container | |
| Intervention | Trials |
| Hypertension | 3 |
| Cerebral Vasospasm | 2 |
| Hypotensive Anesthesia | 1 |
| Nontraumatic Intracerebral Hemorrhage, Multiple Localized | 1 |
| [disabled in preview] | 0 |
| This preview shows a limited data set Subscribe for full access, or try a Trial | |
Clinical Trial Locations for Cardene In 5.0% Dextrose In Plastic Container
Trials by Country
Clinical Trial Progress for Cardene In 5.0% Dextrose In Plastic Container
Clinical Trial Phase
Clinical Trial Sponsors for Cardene In 5.0% Dextrose In Plastic Container
Sponsor Name
